Genetic Causes Found In Many Kazakhstan Children With Epilepsy

What was studied

This study looked at 31 children seen at one tertiary referral center in Kazakhstan for epilepsy or epilepsy-associated neurodevelopmental disorders who were found to have genetic findings considered clinically relevant or potentially relevant.

The researchers reviewed past medical records. They looked at demographics, when seizures started, seizure types, development, EEG and MRI findings, extra-neurological features, treatment response, family history, and genetic test results. Most children had very early seizure onset: the median age at onset was 5 months, and 22 of 31 presented within the first year of life.

What they found

The group showed a wide range of genetic findings and clinical features. Developmental delay or intellectual impairment was reported in about two-thirds of the children, and speech delay, motor delay, and hypotonia were also common. Variants were identified across 23 genes. The largest mechanistic group involved ion channelopathies, followed by mitochondrial or metabolic disorders, mTOR pathway disorders, and neurodevelopmental/chromatin/transcriptional disorders.

SCN1A was the most recurrent gene, found in 8 of 31 children, and was associated with a broad range of presentations, from Dravet-compatible to non-Dravet presentations. EEG and MRI abnormalities were common and often syndromic in pattern. Treatment response was frequently partial or poor overall, but the authors noted selected genotype-linked treatment observations, including carbamazepine in PRRT2, pyridoxine in PNPO, and stiripentol in one SCN1A case.

Limits of the evidence

This was a small, retrospective case series from a single referral center, so it cannot show how common these findings are in all children with epilepsy in Kazakhstan. The children were clinically selected and already had genetic findings judged clinically relevant or potentially relevant, which may bias the picture toward more complex or severe cases.

Because there was no comparison group, the study cannot establish the effect of specific treatments. Some variants had limited prior evidence in databases or published reports, and inheritance or segregation testing was only available in some families, so there is uncertainty for some findings.

For families and caregivers

For families, this study suggests that in babies and children with very early-onset epilepsy, developmental concerns, or syndromic features, genetic testing may help clarify the diagnosis and may sometimes be linked with treatment observations. It also shows that the same gene, especially SCN1A, can be seen with different clinical presentations.

At the same time, the study does not mean every child will get a clear answer or a treatment change. The main message is that combining careful clinical evaluation with genetic testing and family-based analysis may be useful, especially in underrepresented populations where less data have been published.

What to watch next

Larger, multi-center studies with broader patient inclusion and follow-up of treatment outcomes would help extend these findings.

Terms in this summary

tertiary center

A highly specialized hospital or clinic that sees more complex cases.

EEG

A test that records the brain's electrical activity.

MRI

A scan that makes detailed pictures of the brain and body.

SCN1A

A gene linked to several epilepsy syndromes, including some early-onset forms.

Dravet

A severe epilepsy syndrome that usually begins in infancy.

ion channelopathies

Disorders involving genes that affect electrical signaling in cells.

mTOR pathway

A cell-growth signaling pathway; changes in it can be linked to some epilepsy disorders.

segregation analysis

Checking whether a genetic variant is also present in other family members to help judge its importance.